MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure - Concepedia

Concepedia

Publication | Closed Access

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

80

Citations

24

References

2008

Year

Robert Dreicer, Walter M. Stadler, F. R. Ahmann, Theresa L. Whiteside, Nadine Bizouarne, Bruce Acres, Jean‐Marc Limacher, Patrick Squiban, Allan J. Pantuck

Investigational New Drugs

UrologyCancer ImmunosurveillanceMedicineImmunologyTumor ImmunityMva-muc1-il2 Vaccine ImmunotherapyTherapeutic VaccineImmunotherapeuticsProstatic DiseaseImmunotherapyOncologyBiochemical Failure

References

	Year	Citations

Page 1

Page 1